propargylamine






80 Article(s)
Download
PMID
Title
Journal
Pub. Date
#Total Relationship(s)
1 729588 Effect of phospholipid depletion by phospholipases on the properties and formation of the multiple monoamine oxidase forms in the rat liver. Eur J Biochem 1978 Dec 1 1
2 883159 [Inhibition of the activity of monoamine oxidases type A and B by derivatives of 2-propynylamine]. Vopr Med Khim 1977 Mar-Apr 4
3 1094115 Synthesis and biological activity of LH-RH analogs modified at the carboxyl terminus. J Med Chem 1975 Mar 3
4 1433183 Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. J Med Chem 1992 Oct 2 1
5 1567465 The metabolism of aminoacetone to methylglyoxal by semicarbazide-sensitive amine oxidase in human umbilical artery. Biochem Pharmacol 1992 Apr 1 2
6 2128506 Semicarbazide-sensitive amine oxidase activity in rat aortic cultured smooth muscle cells. J Neural Transm Suppl 1990 2
7 3707613 Role of propiolaldehyde and other metabolites in the pargyline inhibition of rat liver aldehyde dehydrogenase. Biochem Pharmacol 1986 May 1 1
8 6615922 [Kinetics of the inhibition of mitochondrial monoamine oxidases A and B from rat liver by 1-(indolyl-3)isopropylmethylpropargylamine]. Biokhimiia 1983 Jul 1
9 7931256 Deamination of aliphatic amines by type B monoamine oxidase and semicarbazide-sensitive amine oxidase; pharmacological implications. J Neural Transm Suppl 1994 1
10 8061623 Relationship between the hydrophobic physicochemical parameters and biological activity of some monoamine oxidase inhibitory drugs. Biochem Mol Biol Int 1994 Apr 1
11 8294932 Neurochemical and neuroprotective effects of some aliphatic propargylamines: new selective nonamphetamine-like monoamine oxidase B inhibitors. J Neurochem 1994 Feb 1
12 8469735 [An increase in the radioprotective effect of O-methyltyramine and mezaton by monoamine oxidase inhibitors]. Radiobiologiia 1993 Jan-Feb 2
13 10893719 Synthesis and antiviral activity of C-5 substituted analogues of d4T bearing methylamino- or methyldiamino-linker arms. Nucleosides Nucleotides Nucleic Acids 2000 May-Jun 1
14 10907720 Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J Neural Transm (Vienna) 1999 1
15 10996018 Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mech Ageing Dev 2000 Jul 31 1
16 11205136 Common properties for propargylamines of enhancing superoxide dismutase and catalase activities in the dopaminergic system in the rat: implications for the life prolonging effect of (-)deprenyl. J Neural Transm Suppl 2000 1
17 11377449 Maintaining mitochondrial membrane impermeability. an opportunity for new therapy in glaucoma? Surv Ophthalmol 2001 May 1
18 11454735 Inhibition of rat liver microsomal CYP1A2 and CYP2B1 activity by N-(2-heptyl)-N-methyl-propargylamine and by N-(2-heptyl)-propargylamine. Drug Metab Dispos 2001 Aug 1
19 11462787 Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann N Y Acad Sci 2001 Jun 1
20 11489679 Future of neuroprotection in Parkinson's disease. Parkinsonism Relat Disord 2001 Oct 1
21 11795516 Do antioxidant strategies work against aging and age-associated disorders? Propargylamines: a possible antioxidant strategy. Ann N Y Acad Sci 2001 Apr 2
22 11860347 The influence of metabolism on the MAO-B inhibitory potency of selegiline. Curr Med Chem 2002 Jan 2
23 11961082 Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther 2002 May 9
24 12043833 Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol Neurobiol 2001 Dec 3
25 12111453 Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, and neuroprotection by propargylamines. J Neural Transm (Vienna) 2002 May 1
26 12721812 Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm (Vienna) 2003 May 3
27 14525944 The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. FASEB J 2003 Dec 1
28 14696044 Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease? Bioessays 2004 Jan 2
29 15035819 Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase. Inflammopharmacology 2003 1
30 15382913 CuBr-catalyzed efficient alkynylation of sp3 C-H bonds adjacent to a nitrogen atom. J Am Chem Soc 2004 Sep 29 1
31 15573406 Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 2005 Jan 1-15 4
32 15621213 Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech Ageing Dev 2005 Feb 3
33 16027398 Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 2005 Aug 2
34 16110345 Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today (Barc) 2005 Jun 2
35 16148027 Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J 2005 Nov 13
36 16675649 Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. Am J Health Syst Pharm 2006 May 15 2
37 16717254 Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. Neurology 2006 May 23 2
38 16927880 [Molecular mechanisms of the neuroprotective effect of (-)-deprenyl]. Orv Hetil 2006 Jul 9 1
39 17017568 Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. J Neural Transm Suppl 2006 4
40 17511474 Mechanistic analysis of a suicide inactivator of histone demethylase LSD1. Biochemistry 2007 Jun 12 1
41 17529991 Structural basis of histone demethylation by LSD1 revealed by suicide inactivation. Nat Struct Mol Biol 2007 Jun 1
42 17982885 Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers. J Neural Transm Suppl 2007 1
43 18035186 Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther 2007 Sep 1
44 18077571 Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann N Y Acad Sci 2007 Dec 2
45 18488080 Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy. Ther Clin Risk Manag 2007 Jun 1
46 18806608 TVP1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity. J Cardiovasc Pharmacol 2008 Sep 2
47 19915070 TVP1022 protects neonatal rat ventricular myocytes against doxorubicin-induced functional derangements. J Pharmacol Exp Ther 2010 Feb 3
48 20148560 Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. J Am Chem Soc 2010 Mar 10 2
49 20555137 Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation. J Alzheimers Dis 2010 4
50 21901055 Modification of Monoaminergic Activity by MAO Inhibitors Influences Methamphetamine Actions. Drug Target Insights 2006 1